Indeed, ADAR1 inhibits ZBP1-mediated activation of NLPR3 inflammatory vesicles and cell death by competitively binding to ZBP1 with RIPK3, ultimately leading to tumor development. This evidence concerns the gene RIPK3 and neoplasm.